lumiracoxib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Lumiracoxib is a COX-2 selective inhibitor nonsteroidal anti-inflammatory drug.   Wikipedia

Chemistry

  • SMILES: Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
  • InChIKey: KHPKQFYUPIUARC-UHFFFAOYSA-N
  • Mol. Mass: 293.73
  • ALogP: 4.16
  • ChEMBL Molecule:
    lumiracoxib  
More Chemistry

Pharmacology

Alternative names

2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid | 2-((2-chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid | cox189 | cox 189 | cox-189 | joicela | lumiracoxib | lumiracoxibum | prexige

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (1)


 

Pain

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Analgesia ()

Arthralgia (Phase 2)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 3)

Healthy Volunteers (Phase 4)

Hypertension (Phase 4)

Kidney Failure, Chronic (Phase 2)

Musculoskeletal Pain (Phase 4)

Osteoarthritis (Phase 4)

Osteoarthritis, Hip (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pain (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue